Pediatric Radiology

, Volume 38, Issue 1, pp 2–17 | Cite as

Wilms tumour: prognostic factors, staging, therapy and late effects

  • Sue C. Kaste
  • Jeffrey S. Dome
  • Paul S. Babyn
  • Norbert M. Graf
  • Paul Grundy
  • Jan Godzinski
  • Gill A. Levitt
  • Helen Jenkinson


Wilms tumour is the most common malignant renal tumour in children. Dramatic improvements in survival have occurred as the result of advances in anaesthetic and surgical management, irradiation and chemotherapy. Current therapies are based on trials and studies primarily conducted by large multi-institutional cooperatives including the Société Internationale d’Oncologie Pédiatrique (SIOP) and the Children’s Oncology Group (COG). The primary goals are to treat patients according to well-defined risk groups in order to achieve the highest cure rates, to decrease the frequency and intensity of acute and late toxicity and to minimize the cost of therapy. The SIOP trials and studies largely focus on the issue of preoperative therapy, whereas the COG trials and studies start with primary surgery. This paper reviews prognostic factors and staging systems for Wilms tumour and its current treatment with surgery and chemotherapy. Surgery remains a crucial part of treatment for nephroblastoma, providing local primary tumour control and adequate staging and possibly controlling the metastatic spread and central vascular extension of the disease. Partial nephrectomy, when technically feasible, seems reasonable not only in those with bilateral disease but also in those with unilateral disease where the patient has urological disorders or syndromes predisposing to malignancy. Partial nephrectomy, however, is frequently not sufficient for an anaplastic variant of tumour. The late effects for Wilms tumour and its treatment are also reviewed. The treatment of Wilms tumour has been a success story, and currently in excess of 80% of children diagnosed with Wilms tumour can look forward to long-term survival, with less than 20% experiencing serious morbidity at 20 years from diagnosis. The late complications are a consequence of the type and intensity of treatment required, which in turn reflects the nature and extent of the original tumour. Continual international trial development and participation will improve matching of treatment needs with prognosis, reducing long-term complications in the majority. The advent of molecular markers of disease severity and improved functional imaging might help.


Nephroblastoma SIOP COG Staging Surgery Preoperative chemotherapy Children 


  1. 1.
    Kim S, Chung DH (2006) Pediatric solid malignancies: neuroblastoma and Wilms’ tumor. Surg Clin North Am 86:469–487, xiPubMedGoogle Scholar
  2. 2.
    Breslow N, Olshan A, Beckwith JB et al (1993) Epidemiology of Wilms tumor. Med Pediatr Oncol 21:172–181PubMedGoogle Scholar
  3. 3.
    Gommersall LM, Arya M, Mushtaq I et al (2005) Current challenges in Wilms’ tumor management. Nat Clin Pract Oncol 2:298–304; quiz 291 p following 324PubMedGoogle Scholar
  4. 4.
    Hartman DJ, MacLennan GT (2005) Wilms tumor. J Urol 173:2147PubMedGoogle Scholar
  5. 5.
    National Cancer Institute (2004) Surveillance Epidemiology and End Results (SEER) Pediatric Monograph. National Cancer Institute, Bethesda, MDGoogle Scholar
  6. 6.
    Coppes MJ, Arnold M, Beckwith JB et al (1999) Factors affecting the risk of contralateral Wilms tumor development: a report from the National Wilms Tumor Study Group. Cancer 85:1616–1625PubMedGoogle Scholar
  7. 7.
    Pritchard-Jones K, Vujanic G (2006) Multiple pathways to Wilms tumor: how much is genetic? Pediatr Blood Cancer 47:232–234PubMedGoogle Scholar
  8. 8.
    de Kraker J, Lemerle J, Voute PA et al (1990) Wilm’s tumor with pulmonary metastases at diagnosis: the significance of primary chemotherapy. International Society of Pediatric Oncology Nephroblastoma Trial and Study Committee. J Clin Oncol 8:1187–1190PubMedGoogle Scholar
  9. 9.
    Beckwith JB (1998) Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Am J Med Genet 79:268–273PubMedGoogle Scholar
  10. 10.
    Qualman SJ, Bowen J, Amin MB et al (2003) Protocol for the examination of specimens from patients with Wilms tumor (nephroblastoma) or other renal tumors of childhood. Arch Pathol Lab Med 127:1280–1289PubMedGoogle Scholar
  11. 11.
    Bonadio JF, Storer B, Norkool P et al (1985) Anaplastic Wilms’ tumor: clinical and pathologic studies. J Clin Oncol 3:513–520PubMedGoogle Scholar
  12. 12.
    Weirich A, Leuschner I, Harms D et al (2001) Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH. Ann Oncol 12:311–319PubMedGoogle Scholar
  13. 13.
    Pritchard-Jones K (1997) Malignant origin of the stromal component of Wilms’ tumor. J Natl Cancer Inst 89:1089–1091PubMedGoogle Scholar
  14. 14.
    Rivera MN, Haber DA (2005) Wilms’ tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 5:699–712PubMedGoogle Scholar
  15. 15.
    Green DM, Beckwith JB, Breslow NE et al (1994) Treatment of children with stages II to IV anaplastic Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol 12:2126–2131PubMedGoogle Scholar
  16. 16.
    Delemarre JF, Sandstedt B, Harms D et al (1996) The new SIOP (Stockholm) working classification of renal tumours of childhood. International Society of Paediatric Oncology. Med Pediatr Oncol 26:145–146PubMedGoogle Scholar
  17. 17.
    Neville HL, Ritchey ML (2000) Wilms’ tumor. Overview of National Wilms’ Tumor Study Group results. Urol Clin North Am 27:435–442PubMedGoogle Scholar
  18. 18.
    Pritchard-Jones K, Kelsey A, Vujanic G et al (2003) Older age is an adverse prognostic factor in stage I, favorable histology Wilms’ tumor treated with vincristine monochemotherapy: a study by the United Kingdom Children’s Cancer Study Group, Wilm’s Tumor Working Group. J Clin Oncol 21:3269–3275PubMedGoogle Scholar
  19. 19.
    Breslow N, Sharples K, Beckwith JB et al (1991) Prognostic factors in nonmetastatic, favorable histology Wilms’ tumor. Results of the Third National Wilms’ Tumor Study. Cancer 68:2345–2353PubMedGoogle Scholar
  20. 20.
    Shamberger RC, Guthrie KA, Ritchey ML et al (1999) Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4. Ann Surg 229:292–297PubMedGoogle Scholar
  21. 21.
    Wilimas JA, Dome JS, Metzger M (2006) Wilms tumor.
  22. 22.
    Grundy PE, Telzerow PE, Breslow N et al (1994) Loss of heterozygosity for chromosomes 16q and 1p in Wilms’ tumors predicts an adverse outcome. Cancer Res 54:2331–2333PubMedGoogle Scholar
  23. 23.
    Grundy RG, Pritchard J, Scambler P et al (1998) Loss of heterozygosity on chromosome 16 in sporadic Wilms’ tumour. Br J Cancer 78:1181–1187PubMedGoogle Scholar
  24. 24.
    Hing S, Lu YJ, Summersgill B et al (2001) Gain of 1q is associated with adverse outcome in favorable histology Wilms’ tumors. Am J Pathol 158:393–398PubMedGoogle Scholar
  25. 25.
    Dome JS, Chung S, Bergemann T et al (1999) High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms’ tumor. Cancer Res 59:4301–4307PubMedGoogle Scholar
  26. 26.
    Dome JS, Bockhold CA, Li SM et al (2005) High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms’ tumor. J Clin Oncol 23:9138–9145PubMedGoogle Scholar
  27. 27.
    Grundy P, Green D, Coppes M (2002) Renal tumors. In: Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  28. 28.
    Tournade MF, Com-Nougue C, de Kraker J et al (2001) Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms’ tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms’ Tumor Trial and Study. J Clin Oncol 19:488–500PubMedGoogle Scholar
  29. 29.
    Graf N, Tournade MF, de Kraker J (2000) The role of preoperative chemotherapy in the management of Wilms’ tumor. The SIOP studies. International Society of Pediatric Oncology. Urol Clin North Am 27:443–454PubMedGoogle Scholar
  30. 30.
    Lemerle J, Voute PA, Tournade MF et al (1976) Preoperative versus postoperative radiotherapy, single versus multiple courses of actinomycin D, in the treatment of Wilms’ tumor. Preliminary results of a controlled clinical trial conducted by the International Society of Paediatric Oncology (S.I.O.P.). Cancer 38:647–654PubMedGoogle Scholar
  31. 31.
    Lemerle J, Voute PA, Tournade MF et al (1983) Effectiveness of preoperative chemotherapy in Wilms’ tumor: results of an International Society of Paediatric Oncology (SIOP) clinical trial. J Clin Oncol 1:604–609PubMedGoogle Scholar
  32. 32.
    Tournade MF, Com-Nougue C, Voute PA et al (1993) Results of the Sixth International Society of Pediatric Oncology Wilms’ Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms’ tumor. J Clin Oncol 11:1014–1023PubMedGoogle Scholar
  33. 33.
    de Kraker J, Graf N, van Tinteren H et al (2004) Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms’ tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet 364:1229–1235PubMedGoogle Scholar
  34. 34.
    D’Angio GJ, Evans AE, Breslow N et al (1976) The treatment of Wilms’ tumor: results of the national Wilms’ tumor study. Cancer 38:633–646PubMedGoogle Scholar
  35. 35.
    D’Angio GJ, Evans A, Breslow N et al (1981) The treatment of Wilms’ tumor: results of the Second National Wilms’ Tumor Study. Cancer 47:2302–2311PubMedGoogle Scholar
  36. 36.
    D’Angio GJ, Breslow N, Beckwith JB et al (1989) Treatment of Wilms’ tumor. Results of the Third National Wilms’ Tumor Study. Cancer 64:349–360PubMedGoogle Scholar
  37. 37.
    Green DM, Breslow NE, Beckwith JB et al (1998) Effect of duration of treatment on treatment outcome and cost of treatment for Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol 16:3744–3751PubMedGoogle Scholar
  38. 38.
    Grundy PE, Breslow NE, Li S et al (2005) Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 23:7312–7321PubMedGoogle Scholar
  39. 39.
    Dome J, Green D (2005) Treatment of anaplastic Wilms’ Tumor: a report from the National Wilms’ Tumor Study Group (abstract 8508). Proceedings of the 41st ASCO Annual Meeting, 13–17 May 2005, Orlando, FLGoogle Scholar
  40. 40.
    Horwitz JR, Ritchey ML, Moksness J et al (1996) Renal salvage procedures in patients with synchronous bilateral Wilms’ tumors: a report from the National Wilms’ Tumor Study Group. J Pediatr Surg 31:1020–1025PubMedGoogle Scholar
  41. 41.
    Sugawara Y, Zasadny KR, Grossman HB et al (1999) Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology 211:249–256PubMedGoogle Scholar
  42. 42.
    Ritchey ML (2005) Renal sparing surgery for Wilms tumor. J Urol 174:1172–1173PubMedGoogle Scholar
  43. 43.
    Ritchey M (2003) Editorial comment for partial nephrectomy for unilateral Wilms tumor results of study SIOP 93-01/GPOH. J Urol 170Google Scholar
  44. 44.
    Gross R (1953) The surgery of infancy and childhood. WB Saunders, PhiladelphiaGoogle Scholar
  45. 45.
    Kung F, Wi N (1982) Cancer Medicine, 2nd edn. Lea & Febiger, Philadelphia, pp 2181–2192Google Scholar
  46. 46.
    de Kraker J, Graf N, van Tinteren H et al (2004) Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms’ tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet 364:1229–1235PubMedGoogle Scholar
  47. 47.
    Jereb B, Tournade MF, Lemerle J et al (1980) Lymph node invasion and prognosis in nephroblastoma. Cancer 45:1632–1636PubMedGoogle Scholar
  48. 48.
    Godzinski J, deKraker J (2004) Is the number of lymph nodes sampled at Wilms tumor nephrectomy predictive for detection of the regional extension of the disease? International Society of Paediatric Oncology, SIOP XXXVI Congress Meeting: Abstracts. Pediatr Blood Cancer 43(4):329Google Scholar
  49. 49.
    Godzinski J, Heij H (2005) Does the pretreatment tumor rupture influence the outcome in patients with nephroblastoma? International Society of Paediatric Oncology, SIOP XXXVII Annual Congress Meeting: Abstracts. Pediatr Blood Cancer 45(4):387Google Scholar
  50. 50.
    Brisse H, Schleiermacher G, Neuenschwander S (2006) Evaluation of 61 nephroblastoma patients with clinical and/or radiological signs of tumor rupture: a single institution study. International Society of Paediatric Oncology, SIOP XXXVIII Congress Meeting: Contents and Abstracts. Pediatr Blood Cancer 47(4):364Google Scholar
  51. 51.
    Ritchey ML, Green DM, Breslow NB et al (1995) Accuracy of current imaging modalities in the diagnosis of synchronous bilateral Wilms’ tumor. A report from the National Wilms Tumor Study Group. Cancer 75:600–604PubMedGoogle Scholar
  52. 52.
    Ritchey ML, Shamberger RC, Hamilton T et al (2005) Fate of bilateral renal lesions missed on preoperative imaging: a report from the National Wilms Tumor Study Group. J Urol 174:1519–1521; discussion 1521PubMedGoogle Scholar
  53. 53.
    Ribeiro RC, Schettini ST, Abib Sde C et al (2006) Cavectomy for the treatment of Wilms tumor with vascular extension. J Urol 176:279–283; discussion 283–274PubMedGoogle Scholar
  54. 54.
    Shamberger RC, Ritchey ML, Haase GM et al (2001) Intravascular extension of Wilms tumor. Ann Surg 234:116–121PubMedGoogle Scholar
  55. 55.
    Godzinski J, Tournade MF, De Kraker J et al (1999) The role of preoperative chemotherapy in the treatment of nephroblastoma: the SIOP experience. Societe Internationale d’Oncologie Pediatrique. Semin Urol Oncol 17:28–32PubMedGoogle Scholar
  56. 56.
    Thompson WR, Newman K, Seibel N et al (1992) A strategy for resection of Wilms’ tumor with vena cava or atrial extension. J Pediatr Surg 27:912–915PubMedGoogle Scholar
  57. 57.
    Daum R, Roth H, Zachariou Z (1994) Tumor infiltration of the vena cava in nephroblastoma. Eur J Pediatr Surg 4:16–20PubMedGoogle Scholar
  58. 58.
    Inserra A (2006) Relationship between the Wilms tumour and the neoplastic thrombosis: does it influence the outcome? International Society of Paediatric Oncology, SIOP XXXVIII Congress Meeting: Contents and Abstracts. Pediatr Blood Cancer 47(4):359Google Scholar
  59. 59.
    Gentil Martins A (1989) Partial nephrectomy for nephroblastoma a plea for less radical surgery. Med Pediatr Oncol 17:320Google Scholar
  60. 60.
    Hoellwarth M (1999) Partial nephrectomy in patients with unilateral Wilms tumor. 3rd International Congress of Paediatric Surgery, 6–8 May, BrusselsGoogle Scholar
  61. 61.
    Moorman C (1994) Partial nephrectomy in unilateral Wilms’ tumor is feasible without local recurrence. Med Pediatr Oncol 23:218Google Scholar
  62. 62.
    Moorman C (1998) Is partial nephrectomy appropriate treatment for unilateral Wilms’ tumour? J Pediatr Surg 33:165–170Google Scholar
  63. 63.
    de Kraker J (1997) Wilms’ tumour stage IV: a report from the SIOP-9 study. Med Pediatr Oncol 29:370Google Scholar
  64. 64.
    Godzinski J (1991) Stage IV nephroblastoma with extrapulmonary metastatic involvement in the SIOP 6 and 9 study. Med Pediatr Oncol 19:371Google Scholar
  65. 65.
    Cozzi DA, Zani A (2006) Nephron-sparing surgery in children with primary renal tumor: indications and results. Semin Pediatr Surg 15:3–9PubMedGoogle Scholar
  66. 66.
    Godzinski J (2001) Local treatment for extrapulmonary metastases in the SIOP-9 initial stage IV Wilms’ tumour patients. Med Pediatr Oncol 37:338Google Scholar
  67. 67.
    Ritchey ML, Kelalis PP, Breslow N et al (1992) Surgical complications after nephrectomy for Wilms’ tumor. Surg Gynecol Obstet 175:507–514PubMedGoogle Scholar
  68. 68.
    Godzinski J, Tournade MF, deKraker J et al (1998) Rarity of surgical complications after postchemotherapy nephrectomy for nephroblastoma. Experience of the International Society of Paediatric Oncology-Trial and Study “SIOP-9”. International Society of Paediatric Oncology Nephroblastoma Trial and Study Committee. Eur J Pediatr Surg 8:83–86PubMedCrossRefGoogle Scholar
  69. 69.
    Ritchey M (2003) Surgical complications following nephrectomy for Wilms tumor. Med Pediatr Oncol 41:251Google Scholar
  70. 70.
    Mankowski P (2004) Minimal invasive pulmonary metastasectomy in stage IV malignancies in children. International Society of Paediatric Oncology, SIOP XXXVI Congress Meeting: Abstracts. Pediatr Blood Cancer 43(4):334Google Scholar
  71. 71.
    Duarte R, Denes F (2005) Further experience with laparoscopic nephrectomy for Wilms’ tumour after chemotheraphy. BJU Int 98:155–159Google Scholar
  72. 72.
    Shamberger RC, Haase GM, Argani P et al (2006) Bilateral Wilms’ tumors with progressive or nonresponsive disease. J Pediatr Surg 41:652–657; discussion 652–657PubMedGoogle Scholar
  73. 73.
    Haecker FM, von Schweinitz D, Harms D et al (2003) Partial nephrectomy for unilateral Wilms tumor: results of study SIOP 93-01/GPOH. J Urol 170:939–942; discussion 934–943PubMedGoogle Scholar
  74. 74.
    Ritchey ML (1996) Primary nephrectomy for Wilms’ tumor: approach of the National Wilms’ Tumor Study Group. Urology 47:787–791PubMedGoogle Scholar
  75. 75.
    Breslow NE, Takashima JR, Ritchey ML et al (2000) Renal failure in the Denys-Drash and Wilms’ tumor-aniridia syndromes. Cancer Res 60:4030–4032PubMedGoogle Scholar
  76. 76.
    Ritchey M (2004) Editorial comment to conservative management of hyperplastic and multicentric nephroblastomatosis by Cozzi F. J Urol 172:1069–1070Google Scholar
  77. 77.
    Wu HY, Snyder HM 3rd, D’Angio GJ (2005) Wilms’ tumor management. Curr Opin Urol 15:273–276PubMedGoogle Scholar
  78. 78.
    Dome JS, Liu T, Krasin M et al (2002) Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children’s Research Hospital. J Pediatr Hematol Oncol 24:192–198PubMedGoogle Scholar
  79. 79.
    Abu-Ghosh AM, Krailo MD, Goldman SC et al (2002) Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms’ tumor: a Children’s Cancer Group report. Ann Oncol 13:460–469PubMedGoogle Scholar
  80. 80.
    Pein F, Pinkerton R, Tournade MF et al (1993) Etoposide in relapsed or refractory Wilms’ tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children’s Cancer Study Group. J Clin Oncol 11:1478–1481PubMedGoogle Scholar
  81. 81.
    Campbell AD, Cohn SL, Reynolds M et al (2004) Treatment of relapsed Wilms’ tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children’s Memorial Hospital. J Clin Oncol 22:2885–2890PubMedGoogle Scholar
  82. 82.
    Mertens AC, Yasui Y, Neglia JP et al (2001) Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 19:3163–3172PubMedGoogle Scholar
  83. 83.
    Curry HL, Parkes SE, Powell JE et al (2006) Caring for survivors of childhood cancers: the size of the problem. Eur J Cancer 42:501–508PubMedGoogle Scholar
  84. 84.
    Pritchard-Jones K, Pritchard J (2004) Success of clinical trials in childhood Wilms’ tumour around the world. Lancet 364:1468–1470PubMedGoogle Scholar
  85. 85.
    Bailey S, Roberts A, Brock C et al (2002) Nephrotoxicity in survivors of Wilms’ tumours in the North of England. Br J Cancer 87:1092–1098PubMedGoogle Scholar
  86. 86.
    Kremer LC, van der Pal HJ, Offringa M et al (2002) Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 13:819–829PubMedGoogle Scholar
  87. 87.
    Sorensen K, Levitt G, Sebag-Montefiore D et al (1995) Cardiac function in Wilms’ tumor survivors. J Clin Oncol 13:1546–1556PubMedGoogle Scholar
  88. 88.
    Marx M (2002) A multicentre analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP 9/GPOH and SIOP 93-01/GPOH. Med Pediatr Oncol 39:18–24PubMedGoogle Scholar
  89. 89.
    Levitt G, Bunch K, Rogers CA et al (1996) Cardiac transplantation in childhood cancer survivors in Great Britain. Eur J Cancer 32A:826–830PubMedGoogle Scholar
  90. 90.
    Sorensen K, Levitt GA, Bull C et al (2003) Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 97:1991–1998PubMedGoogle Scholar
  91. 91.
    Pein F, Sakiroglu O, Dahan M et al (2004) Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 91:37–44PubMedGoogle Scholar
  92. 92.
    Shalet SM, Gibson B, Swindell R et al (1987) Effect of spinal irradiation on growth. Arch Dis Child 62:461–464PubMedGoogle Scholar
  93. 93.
    Makiprnaa A (1993) Spinal deformity induced by radiotherapy for solid tumours in childhood: a long-term study. Eur J Pediatr Surg 152:197–200Google Scholar
  94. 94.
    Wallace WH, Shalet SM, Morris-Jones PH et al (1990) Effect of abdominal irradiation on growth in boys treated for a Wilms’ tumor. Med Pediatr Oncol 18:441–446PubMedGoogle Scholar
  95. 95.
    Counsell R, Bain G, Williams MV et al (1996) Artificial radiation menopause: where are the ovaries? Clin Oncol (R Coll Radiol) 8:250–253Google Scholar
  96. 96.
    Wallace WH, Shalet SM, Crowne EC et al (1989) Ovarian failure following abdominal irradiation in childhood: natural history and prognosis. Clin Oncol (R Coll Radiol) 1:75–79Google Scholar
  97. 97.
    Hawkins MM, Smith RA (1989) Pregnancy outcomes in childhood cancer survivors: probable effects of abdominal irradiation. Int J Cancer 43:399–402PubMedGoogle Scholar
  98. 98.
    Green DM, Whitton JA, Stovall M et al (2002) Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol 187:1070–1080PubMedGoogle Scholar
  99. 99.
    Nussbaum Blask AR, Nicholson HS, Markle BM et al (1999) Sonographic detection of uterine and ovarian abnormalities in female survivors of Wilms’ tumor treated with radiotherapy. Am J Roentgenol 172:759–763Google Scholar
  100. 100.
    Nicholson HS, Blask AN, Markle BM et al (1996) Uterine anomalies in Wilms’ tumor survivors. Cancer 78:887–891PubMedGoogle Scholar
  101. 101.
    Byrne J, Nicholson HS (2002) Excess risk for Mullerian duct anomalies in girls with Wilms tumor. Med Pediatr Oncol 38:258–259PubMedGoogle Scholar
  102. 102.
    Breslow NE, Collins AJ, Ritchey ML et al (2005) End stage renal disease in patients with Wilms tumor: results from the National Wilms Tumor Study Group and the United States Renal Data System. J Urol 174:1972–1975PubMedGoogle Scholar
  103. 103.
    Libshitz H, Cohen MA (1982) Radiation-induced osteochondromas. Radiology 142:643–647PubMedGoogle Scholar
  104. 104.
    Walker DA, Dillon M, Levitt G et al (1992) Multiple exostosis (osteochondroma) and Wilms’ tumour – a possible association. Med Pediatr Oncol 20:360–361PubMedGoogle Scholar
  105. 105.
    Breslow NE, Takashima JR, Whitton JA et al (1995) Second malignant neoplasms following treatment for Wilm’s tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol 13:1851–1859PubMedGoogle Scholar
  106. 106.
    Carli M, Frascella E, Tournade MF et al (1997) Second malignant neoplasms in patients treated on SIOP Wilms tumour studies and trials 1, 2, 5, and 6. Med Pediatr Oncol 29:239–244PubMedGoogle Scholar
  107. 107.
    Hawkins MM, Wilson LM, Burton HS et al (1996) Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 88:270–278PubMedGoogle Scholar
  108. 108.
    Garwicz S, Anderson H, Olsen JH et al (2000) Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer 88:672–678PubMedGoogle Scholar
  109. 109.
    Neglia JP, Friedman DL, Yasui Y et al (2001) Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 93:618–629PubMedGoogle Scholar
  110. 110.
    Hawkins MM, Draper GJ, Kingston JE (1987) Incidence of second primary tumours among childhood cancer survivors. Br J Cancer 56:339–347PubMedGoogle Scholar
  111. 111.
    Tucker MA, D’Angio GJ, Boice JD Jr. et al (1987) Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 317:588–593PubMedCrossRefGoogle Scholar
  112. 112.
    Oeffinger KC, Mertens AC, Sklar CA et al (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572–1582PubMedGoogle Scholar
  113. 113.
    Landier W, Bhatia S, Eshelman DA et al (2004) Development of risk-based guidelines for pediatric cancer survivors: the Children’s Oncology Group Long-Term Follow-Up Guidelines from the Children’s Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 22:4979–4990PubMedGoogle Scholar
  114. 114.
    Landier W, Wallace WH, Hudson MM (2006) Long-term follow-up of pediatric cancer survivors: education, surveillance, and screening. Pediatr Blood Cancer 46:149–158PubMedGoogle Scholar
  115. 115.
    Ehrlich PF (2001) Wilms tumor: progress to date and future considerations. Expert Rev Anticancer Ther 1:555–564PubMedGoogle Scholar
  116. 116.
    Wilimas JA, Kaste SC, Kauffman WM et al (1997) Use of chest computed tomography in the staging of pediatric Wilms’ tumor: interobserver variability and prognostic significance. J Clin Oncol 15:2631–2635PubMedGoogle Scholar
  117. 117.
    Taylor RE (1997) Morbidity from abdominal radiotherapy in the First United Kingdom Children’s Cancer Study Group Wilms’ Tumour Study. United Kingdom Children’s Cancer Study Group. Clin Oncol (R Coll Radiol) 9:381–384Google Scholar
  118. 118.
    Reinhard H, Semler O, Burger D et al (2004) Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor. Klin Paediatr 216:132–140Google Scholar
  119. 119.
    Green DM, Donckerwolcke R, Evans AE et al (1995) Late effects of treatment for Wilms tumor. Hematol Oncol Clin North Am 9:1317–1327PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Sue C. Kaste
    • 1
  • Jeffrey S. Dome
    • 2
  • Paul S. Babyn
    • 3
  • Norbert M. Graf
    • 4
  • Paul Grundy
    • 5
  • Jan Godzinski
    • 6
  • Gill A. Levitt
    • 7
  • Helen Jenkinson
    • 8
  1. 1.Department of Radiological SciencesSt. Jude Children’s Research HospitalMemphisUSA
  2. 2.Department of OncologySt. Jude Children’s Research HospitalMemphisUSA
  3. 3.Department of RadiologyHospital for Sick ChildrenTorontoCanada
  4. 4.Clinic for Pediatric Oncology and HematologyUniversity Hospital of the SaarlandHomburgGermany
  5. 5.Division of Pediatric Hematology, Oncology and Palliative Care, and Northern Alberta Children’s Cancer ProgramUniversity of AlbertaEdmontonCanada
  6. 6.Department of Oncological Surgery for Children and AdolescentsMother and Child InstituteWarsawPoland
  7. 7.Paediatric OncologyGreat Ormond Street Hospital for Sick Children NHS TrustLondonUK
  8. 8.Oncology DepartmentBirmingham Children’s Hospital NHS TrustBirminghamUK

Personalised recommendations